Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CorMedix Inc CRMD

Healthcare
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections... see more

Recent & Breaking News (NDAQ:CRMD)

CorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million

Accesswire April 28, 2017

CorMedix Inc. Announces $10 Million Underwritten Public Offering

Accesswire April 27, 2017

CorMedix Inc. Reports Update on Neutrolin(R) Phase 3 LOCK-IT 100 Clinical Trial

Accesswire April 20, 2017

CorMedix Inc. Secures First European Commercial Collaboration for Neutrolin(R)

Accesswire April 12, 2017

CorMedix Inc. Makes NYSE MKT Section 610(b) Public Announcement

Accesswire March 23, 2017

CorMedix Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

Accesswire March 17, 2017

CorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update

Accesswire March 10, 2017

CorMedix Inc. Appoints John L. (Jack) Armstrong to Senior Leadership Team

Accesswire March 2, 2017

CorMedix Inc. Announces New Appointments to Senior Leadership Team

Accesswire February 1, 2017

CorMedix Inc. Announces Dismissal of Shareholder Derivative Action Lawsuit and Stipulation to Forego Appeal

Accesswire January 9, 2017

CorMedix to Present at Biotech Showcase 2017

Accesswire January 5, 2017

CorMedix Inc. Announces Dismissal of Securities Class Action Lawsuit and Stipulation to Forego Appeal

Accesswire December 21, 2016

Research Reports Initiation on Biotech Stocks -- CorMedix, Trevena, Regulus Therapeutics, and ImmunoCellular Therapeutics

PR Newswire December 13, 2016

CorMedix Inc. Reports Third Quarter 2016 Financial Results and Provides Business Updates

Accesswire November 10, 2016

CorMedix Inc. to Report Third Quarter 2016 Financial Results

Accesswire November 2, 2016

CorMedix Inc. Appoints Khoso Baluch as Chief Executive Officer

Accesswire October 3, 2016

CorMedix Inc. to Present at Multiple Investor and Industry Conferences

Accesswire September 20, 2016

Watch These 5 Huge Put Purchases In Friday Trade

Benzinga.com  September 16, 2016

CorMedix, Inc. Announces Signing of an Agreement with POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium), to Develop CRMD-005, a Proprietary Formulation of Taurolidine, for Rare Orphan Pediatric Tumors

Accesswire September 15, 2016

CorMedix Inc. to Present at 2016 Rodman & Renshaw 18th Annual Global Investment Conference

Accesswire September 6, 2016